ENTER


Полный размерЗакрыть

The modern concept of classification, pathogenesis, clinical manifestations, diagnosis and treatment of endocrine ophthalmopathy

Details
Written by Super User
Category: #2 (04) 2016
Published: 13 November 2017
Hits: 1300

 Polyakova S. I., Maletskyy A. P., Kayаli A.

The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odesa, Ukraine

 Summary. A review of the literature on the classification, pathogenesis, clinical manifestations, diagnosis and treatment of endocrine ophthalmopathy (EOP). It is shown that the existing classification sufficiently reflect the degree of activity, the severity of the pathological process and compensation in orbit, and in the thyroid glande (final state substantially not considered). The clinical picture is very diverse. The main pathogenetic treatment is the use of corticosteroids as a topically (as parabulbar injection) or systemically (in the form of oral and injectable administration). Surgical treatment of EOP is generally carried out at stabilization process in the inactive phase in fibrosis. Despite all the advances in diagnosis and treatment of patients with EOP, there are still a number of outstanding issues in relation to the pathogenesis, classification, clinical course, early diagnosis, prevention and treatment of optic neuropathy, the feasibility of immunomodulation, which should determine the direction of future research in this area.

 Keywords: endocrine ophthalmopathy, classification, pathogenesis, clinical manifestations, diagnosis, treatment. 

REFERENCES

  1. Abdazova R. B., Nugmanova L. B., Chzhen T. R. Endocrine ophthalmopathy: etiology, pathogenesis, classification, clinic, treatment. Mezhdunarodnyy endokrinologicheskiy zhurnal [International journal of endocrinology]. 2009; (24): 24–31 (in Russian).
  2. Brovkina A. F. Endocrinal ophthalmopathy. Moscow: GEOTAR-Media, 2008, 184 p. (in Russian).
  3. Brovkina A. F., Pavlova T. L. Endocrinal ophthalmopathy from the standpoint of an ophthalmologist and endocrinologist. Russkiy meditsinskiy zhurnal [Russian medical journal]. 2004; (208): 539–549 (in Russian).
  4. Brovkina A. F., Tyutyunnikova A. M. On the method of assessment of the clinical course of edematous exophthalmos and psevdotumora. Vestnik oftalmologii [Bulletin of ophthalmology]. 1990; (2): 16–19 (in Russian).  
  5. Krassas G., Versinga V. Modern concepts of diagnosis and treatment of endocrine ophthalmopathy. Thyroid international. 2007; (3): 102–113 (in Russian).
  6. Kuznetsova A. V., Arefeva Ye. V., Volkova Ye. A. Endocrinal ophthalmopathy. Saint Petersburg, 2006, 47 p. (in Russian).
  7. Аmаnо Y., Amano М., Kumazaki Т. Normal contrast enhancement of extraocular masses: fat-suppressed MR findings. American Journal of Neuroradiology. 1997; (18): 161–164.
  8. Bahn R. S. Graves’ ophthalmopathy. The New England Journal of Medicine. 2010; (362): 726–738.
  9. Balazs C., Kiss E., Vamos A., Molnar I., Farid N. R. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy. Journal of Clinical Endocrinology & Metabolism. 1998; (88): 1999–2002.
  10. Bartalena L. Glucocorticoids for Graves’ ophthalmopathy: how and when. The Journal of Clinical Endocrinology & Metabolism. 2005; (90): 5497–5499.
  11. Bartalena L., Pinchere A., Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocrine Reviews. 2000; (21): 168–199.
  12. Bartalena L., Marcocci C., Tanda M. Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid. 2002; (12): 245–250.
  13. Boergen K. P. Ophthalmological diagnosis in autoimmune orbitopathy. Experimental and Clinical Endocrinology & Diabetes. 1991; (97): 235–242.
  14. Bogdanici C., Marcu C. Graves’ ophthalmopathy – a prospective clinical study. Ophthalmologia. 1999; (48): 19–25.
  15. Bouzas E. A., Karadimas P., Mastorakos G., Koutras D. A. Antioxidant agents in the treatment of Graves’ ophthalmopathy. American Journal of Ophthalmology. 2000; (129): 618–622.
  16. Burch H. B., Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. 1993; (14): 747–793.
  17. Cockerham K. P., Hidayat A. A., Brown H. G., Cockerham G. C., Graner S. R. Clinicopathologic evaluation of the Muller muscle in thyroid-associated orbitopathy. British Journal of Ophthalmology. 2002; (86): 102–104.
  18. Cockerham K. P., Kennerdell J. S. Does radiotherapy have a role in the management of thyroid orbitopathy? View. British Journal of Ophthalmology. 2002; (86): 102–107.
  19. Dickinson A. J. Clical manifestations. Graves’ orbitopathy. A multidisciplinary approach. Karger, 2007, pp. 1–26.
  20. Ebner R. Dysthyroid optic neuropathy. Seminars in Ophthalmology. 2002; (17): 18–21.
  21. Goh M., McNab A. Orbital decompression in Graves’ orbitopathy efficacy and safety. Internal Medicine Journal. 2005; (35): 586–591.
  22. Gorman C. A., Garrity J. A., Fatourechi V., Bahn R. S., Petersen I. A., Stafford S. L., Earle J. D., Forbes G. S., Kline R. W., Bergstralh E. J., Offord K. P., Rademacher D. M., Stanley N. M., Bartley G. B. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001; (108): 1523–1534.
  23. Gorman C. A., Garrity J. A., Fatourechi V., Bahn R. S., Petersen I. A., Stafford S. L., Earle J. D., Forbes G. S., Kline R. W., Buettner H., Robertson D. M., Bergstralh E. J., Offord K. P., Rademacher D. M., Stanley N. M., Bartley G. B. The aftermath of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2002; (109): 2100–2107.
  24. Gracia Naya M., Usón M., López-López A., Tapiador M. J., Ara J. R. Thyroid ophthalmopathy as a unique clinical manifestation of thyrotoxicosis. Revue Neurologique. 1995; (23): 1059–1062.
  25. Henzen C. Hyperthyreoidose – Differenzialdiagnose und differezierte Therapie. Schweizerische Rundschau fur Medizin Praxis. 2003; (92): 18–24.
  26. Heufelder A. E. Patogenesis of ophthalmopathy in autoimmune thyroid disease. Reviews in Endocrine and Metabolic Disorders. 2000; (1): 87–95.
  27. Kim J., LaBree L., Levin L., Feldon S. E. The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. British Journal of Ophthalmology. 2004; (88): 72–74.
  28. Kubo T., Shimizu J., Furujo M., Takeuchi A., Yoshioka-Iwaso H., Eguchi N., Fukuhara S., Koyama T., Kanadani T., Shiraga H., Oshima K. An infant case of Graves’ disease with ophthalmopathy. Endocrine Journal. 2005; (52): 647–650.
  29. Lazarus J. H. Relation between thyroid eye disease and type of treatment of Graves’ hyperthyroidism. Thyroid. 1998; (8): 437.
  30. Looi A. L., Luu C. D., Wong T. Y., Seah L. L., Rootman J. Factors associated with decompression and strabismus surgery in thyroid eye disease. Annals of the Academy of Medicine, Singapore. 2005; (34): 154–157.
  31. Mann K. Risk of smoking in thyroid-associated orbitopathy. Experimental and Clinical Endocrinology & Diabetes. 1999; (107): 164–167.
  32. Marcocci C., Bartalena L., Rocchi R., Marinò M., Menconi F., Morabito E., Mazzi B., Mazzeo S., Sartini M. S., Nardi M., Cartei F., Cionini L., Pinchera A. Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism. 2003; (88): 3561–3566.
  33. Marcocci C., Bruno-Bossio G., Manetti L., Tanda M. L., Miccoli P., Iacconi P., Bartolomei M. P., Nardi M., Pinchera A., Bartalena L. The course of Graves’ ophthalmopathy is not influenced by near total theroiectomy: a case-control study. Clinical Endocrinology. 1999; (51): 503–508.
  34. Martins J. R., Furlanetto R. P., Oliveira L. M., Mendes A., Passerotti C. C., Chiamolera M. I., Rocha A. J., Manso P. G., Nader H. B., Dietrich C. P., Maciel R. M. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Grave’s ophthalmopathy. Clinical Endocrinology. 2004; (60): 726–733.
  35. Murakami Y., Kanamoto T., Tuboi T., Maeda T., Inoue Y. Evaluation of extraocular muscle enlargement in dysthyroid ophthalmopathy. Japanese Journal of Ophthalmology. 2001; (45): 622–627.
  36. Ng C. M., Yuen H. K., Choi K. L., Chan M. K., Yuen K. T., Ng Y. W., Tiu S. C. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Medical Journal. 2005; (11): 320–321.
  37. Ohtsuka K., Sato A., Kawaguchi S., Hashimoto M., Suzuki Y. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy. American Journal of Ophthalmology. 2003; (135): 285–290.
  38. Perros P., Dickinson A. J., Kendall-Taylor P. Clinical presentation and natural history of Graves’ ophthalmopathy. In: Bahn R. Thyroid eye disease. Boston: Kluwer Academic Publishers, 2001, pp. 119–138.
  39. Perros P., Kendall-Taylor P. Natural history of thyroid eye disease. Thyroid. 1998; (8): 423–425.
  40. Perros P., Dickinson A. J. Ophthalmopathy. In: Braverman L. E., Utiger R. D. (eds.) Werner and Ingbar’s The Thyroid. A Fundamental and Clinical Text, 9th Ed. Boston: Lippincott Williams & Wilkins, 2005, pp. 474–487.
  41. Prummel M. F., Bakker A., Wiersinga W. M., Baldeschi L., Mourits M. P., Kendall-Taylor P., Perros P., Neoh C., Dickinson A. J., Lazarus J. H., Lane C. M., Heufelder A. E., Kahaly G. J., Pitz S., Orgiazzi J., Hullo A., Pinchera A., Marcocci C., Sartini M. S., Rocchi R., Nardi M., Krassas G. E., Halkias A. Clinical study: multicenter study on characteristics and treatment strategies of patients with Graves’ orbitopathy: the first EUGOGO experience. European Journal of Endocrinology. 2003; (148): 491–495.
  42. Prummel M. F., Bakker A., Wiersinga W. M., Baldeschi L., Mourits M. P., Kendall-Taylor P., Perros P., Neoh C., Dickinson A. J., Lazarus J. H., Lane C. M., Heufelder A. E., Kahaly G. J., Pitz S., Orgiazzi J., Hullo A., Pinchera A., Marcocci C., Sartini M. S., Rocchi R., Nardi M., Krassas G. E., Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. European Journal of Endocrinology. 2003; (148): 491–495.
  43. Rubin P. A., Watkins L. M., Rumelt S., Sutula F. C., Dallow R. L. Orbital computed tomographic characteristics of globe subluxation in thyroid orbitopathy. Ophthalmology. 1998; (105): 2061–2064.
  44. Robert P. Y., Camezind P., Adenis J. P. Complications de l’ophtalmopathie dysthyroidienne. Journal Français d’Ophtalmologie. 2004; (27): 819–821.
  45. Salvi M., Vannucchi G., Campi I., Rossi S., Bonara P., Sbrozzi F., Guastella C., Avignone S., Pirola G., Ratiglia R., Beck-Peccoz P. Efficacy of rituximal treatment for thyroid-associated ophthalmopathy. European Journal of Endocrinology. 2006; (154): 511–517.
  46. Schaefer U., Hesselmann S., Micke O., Schueller P., Bruns F., Palma C., Willich N. A longterm follow-up study after retro-orbital irradiation for Graves’ ophthalmopathy. International Journal of Radiation Oncology, Biology, Physics. 2002; (52): 192–197.
  47. Steinsapir K., Goldberg R. Orbital radiation therapy for Graves’ ophthalmopathy. Ophthalmology. 2003; (110): 451–452.
  48. Van Dyk H. J. Orbital Graves’ disease. A modification of the “NOSPECS” classification. Ophthalmology. 1981; (88): 479–483.
  49. Wasowska M., Janik J., Zgliczynski S. Ocular hydrodynamics in patients with infiltrative edematous exophthlamos in Graves’ disease. Klinika Oczna. 1990; (92): 237–238.
  50. Wiersinga W. M., Prummel M. F. Pathogenesis of Graves’ ophthalmopathy – current understanding. The Journal of Clinical Endocrinology & Metabolism. 2001; (86): 501–503.
  51. Wiersinga W. M. Thyroid associated ophthalmopathy: pediatric and endocrine aspects. Pediatric Endocrinology Reviews. 2004; (1): 435–441.
  52. Yassur I., Ben Simon G. J., Rosen N. Thyroid orbitopathy. Harefuah. 2003; (142): 377–380. 

Received: 1 Apr. 2016

Published: July 2016